Intranasal Drug Delivery of Olanzapine-Loaded Chitosan Nanoparticles

被引:50
作者
Baltzley, Sarah [1 ]
Mohammad, Atiquzzaman [2 ]
Malkawi, Ahmad H. [3 ]
Al-Ghananeem, Abeer M. [1 ]
机构
[1] Sullivan Univ, Coll Pharm, Louisville, KY 40205 USA
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] US WorldMeds LLC, Louisville, KY USA
来源
AAPS PHARMSCITECH | 2014年 / 15卷 / 06期
关键词
bioavailability; intranasal; nanoparticles; olanzapine; pharmacokinetic; WEIGHT-GAIN; IN-VITRO; SALMON-CALCITONIN; NASAL ABSORPTION; INSULIN; SYSTEM; PHARMACOKINETICS; SCHIZOPHRENIA; FORMULATIONS;
D O I
10.1208/s12249-014-0189-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate olanzapine (OZ) systemic absolute bioavailability after intranasal (i.n.) administration in vivo to conscious rabbits. Furthermore, the study investigated the potential use of chitosan nanoparticles as a delivery system to enhance the systemic bioavailability of olanzapine following intranasal administration. Olanzapine-loaded chitosan nanoparticles were prepared through ionotropic gelation of chitosan with tripolyphosphate anions and studied in terms of their size, drug loading, and in vitro release. The OZ nanoparticles were administered i. n. to rabbits, and OZ plasma concentration at predetermined time points was compared to i. n. administration of OZ in solution. The concentrations of OZ in plasma were analyzed by ultra performance liquid chromatography mass spectroscopy (UPLC/MS). OZ-loaded chitosan nanoparticles significantly (p<0.05) enhanced systemic absorption with 51 +/- 11.2% absolute bioavailability as compared to 28 +/- 6.7% after i. n. administration of OZ solution. The results of the present study suggest that intranasal administration of OZ-loaded chitosan nanoparticles formulation could be an attractive modality for delivery of OZ systemically.
引用
收藏
页码:1598 / 1602
页数:5
相关论文
共 41 条
[11]   Nasal pH measurement: a reliable and repeatable parameter [J].
England, RJA ;
Homer, JJ ;
Knight, LC ;
Ell, SR .
CLINICAL OTOLARYNGOLOGY, 1999, 24 (01) :67-68
[12]   Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine [J].
Fuller, MA ;
Shermock, KM ;
Secic, M ;
Grogg, AL .
PHARMACOTHERAPY, 2003, 23 (08) :1037-1043
[13]   THE RELEVANCE OF NASAL PHYSIOLOGY TO THE DESIGN OF DRUG ABSORPTION STUDIES [J].
GIZURARSON, S .
ADVANCED DRUG DELIVERY REVIEWS, 1993, 11 (03) :329-347
[14]   In vitro evaluation of the mucoadhesive properties of chitosan microspheres [J].
He, P ;
Davis, SS ;
Illum, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 166 (01) :75-88
[15]   Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep [J].
Hinchcliffe, M ;
Jabbal-Gill, I ;
Smith, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (06) :681-687
[16]   Intranasal drug delivery [J].
Hussain, AA .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :39-49
[17]  
Illum L, 1998, PHARM RES-DORDR, V15, P1326
[18]   Chitosan as a novel nasal delivery system for vaccines [J].
Illum, L ;
Jabbal-Gill, I ;
Hinchcliffe, M ;
Fisher, AN ;
Davis, SS .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 51 (1-3) :81-96
[19]  
Keck PE, 2002, J CLIN PSYCHIAT, V63, P3
[20]  
Kumar M, 2008, J DRUG TARGET, V16, P806, DOI [10.1080/10611860802476504, 10.1080/10611860802476504 ]